Mindray shareholders to meet in Hong Kong; Tyber Medical raises new funding;

@FierceMedDev: Becton Dickinson boost its quarterly dividend. Item | Follow @FierceMedDev

@MarkHFierce: J&J's $2.5B hip implant settlement offer is already beginning to generate some flack from patients. Story via NYT | Follow @MarkHFierce

> New Jersey's Tyber Medical closed a private placement equity round for an undisclosed amount. Plans call for using the money to accelerate marketing of its TyPEEK titanium plasma sprayed interbody fusion devices. Item

> Chinese medical device giant Mindray Medical ($MR) will hold its 2013 annual meeting at its Hong Kong offices on Dec. 17. Item

> Shareholders of Interlace Medical, which Hologic ($HOLX) snatched up in 2011, are suing the maker of women's health products for nearly $15 million in additional payments. Story

> Topera is touting results from a new independent multicenter clinical study showing that its 3-D mapping system helped improve long-term outcomes for atrial fibrillation patients. Item

> Bruker ($BRKR) won FDA clearance to market its new MALDI Biotyper CA System to identify gram-negative bacterial colonies cultured from human specimens. Item

Biotech News

@FierceBiotech: In our latest report, we feature the top women in the biotech industry. Report | Follow @FierceBiotech

@JohnCFierce: Sanofi might want to re-evaluate its cancer strategy about now. Iniparib and fedratinib both written off in '13. More | Follow @JohnCFierce

@DamianFierce: Pro-23andMe petition aims to protect "potentially life-saving diagnostic kits," thereby making the FDA's case. Petition | Follow @DamianFierce

@EmilyMFierce: Harvard study: 30% of all medical tests are probably unnecessary. More | Follow @EmilyMFierce

> Bayer's $2.4B bid to buy Algeta fits neatly with cancer drug strategy. Story

> Sanofi, Merrimack rack up third straight failure for lead cancer drug. Article

> BTG wins FDA OK for varicose vein treatment, projects $500M peak. Story

Pharma News

@FiercePharma: Monday's top story: Who leaked the scary Copaxone numbers? Teva intends to find out. Story | Follow @FiercePharma

@EricPFierce: Any who thinks women aren't controlling the destiny of biopharma would be wrong. Women in Biotech 2013 Report | Follow @EricPFierce

@CarlyHFierce: FDA withdraws restrictions on GSK diabetes drug Avandia - too little, too late? Story | Follow @CarlyHFierce

> Mylan, Biocon ready to roll out Herceptin biosimilar in India. Story

> FDA withdraws restrictions on GSK's Avandia. News

> Bayer bids $2.4B for Xofigo partner Algeta in drive for cancer growth. More

Pharma Manufacturing News

> JLL expects to buy more CMOs. Story

> Glaxo piles onto API expansion in Scotland. More

> PL Developments, Aaron combine expertise in OTC manufacturing. Article

> Ranbaxy ready to bail on vaccine manufacturing. More

> Bafna draws buyout interest for its European-approved manufacturing. News

Biotech Research News

> Eli Lilly, Project A.L.S. forge preclinical drug discovery pact. News

> Biota halts preclinical antibiotics program as antimicrobial resistance grows. Report

> New targets for Parkinson's revealed in gene network. Story

> Antibiotics may weaken body's response to cancer therapies. Article

> New York Stem Cell Foundation, NIH partner to study rare diseases. Story

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.